Clinical trials: Myeloid
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML)
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a…
- Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS), Juvenile Myelomonocytic Leukaemias (JMML)
- Trial name
- NCT02333058
- Testing
- Treosulfan
- Where
- 24 sites in Austria, Czechia and 4 more
- Volunteers
- 70 people
- Sponsor
- medac GmbH
Leukemia, Myeloid, Acute
Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a phase 2, single-arm, open-label, multi-center study to establish the safety and efficacy of Troxatyl™ (troxacitabine) administered as a continuous infusion for 5 days to subjects with AML.
- Trial name
- NCT00129948
- Testing
- Troxatyl™ (troxacitabine)
- Where
- 20 sites in United States
- Volunteers
- 211 people
- Sponsor
- SGX Pharmaceuticals, Inc.
Leukemia, Myelomonocytic, Chronic
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
The goal of this clinical trial is to learn if pacritinib works better than hydroxyurea to treat advanced proliferative chronic myelomonocytic leukemia in adults.
- Trial name
- PROSPERA (NCT07033598)
- Testing
- Pacritinib, Hydroxyurea
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 66 people
- Sponsor
- Theradex
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07216443
- Testing
- Orca-T
- Where
- 6 sites in United States
- Volunteers
- 80 people
- Sponsor
- Orca Biosystems, Inc.
Leukemia, Myeloid, Acute
A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
This is a multicenter, double-blind, randomized, placebo-controlled study designed to compare overall survival in participants with relapsed or refractory AML treated with idasanutlin in combination with cytarabine versus…
- Trial name
- MIRROS (NCT02545283)
- Testing
- Cytarabine, Idasanutlin
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 447 people
- Sponsor
- Hoffmann-La Roche
Chronic Myelogenous Leukemia
Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)
The primary purpose of this study is to compare the efficacy of polyethylene glycol (PEG; pegylated) interferon alfa-2b (PEG Intron, C98026) versus interferon alfa-2b (Intron® A) in the treatment of participants with newly…
- Trial name
- NCT03547154
- Testing
- Pegylated interferon alfa-2b, Interferon alfa-2b
- Volunteers
- 344 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Myeloid, Acute, Hematologic Neoplasms
Trial of Pimasertib in Hematological Malignancies
This is an open-label, multi-center, dose-escalation trial of pimasertib (MSC1936369B) in blood and bone marrow cancers. The trial will be conducted in two parts: Part 1 (safety run-in period): Will determine the maximum…
- Trial name
- NCT00957580
- Testing
- Pimasertib
- Where
- 9 sites in United States, France
- Volunteers
- 81 people
- Sponsor
- EMD Serono
Chronic Lymphocytic Leukemia, Multiple Myeloma
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT04887259
- Testing
- LAVA-051, Interleukin 2
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 16 people
- Sponsor
- Lava Therapeutics
Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
This is a Phase II open label study of crenolanib besylate. This study will enroll subjects with relapsed or refractory AML with FLT3 activating mutations. Prior treatment with other FLT3 TKIs is allowed.
- Trial name
- NCT01522469
- Testing
- Crenolanib Besylate (CP-868,596-26)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Acute Myelogenous Leukemia (AML)
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
This is a dose-escalation phase I trial to evaluate the safety and tolerability of MAX-40279 in subjects with acute myelogenous leukemia(AML).
- Trial name
- NCT03412292
- Testing
- MAX-40279
- Where
- 4 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Maxinovel Pty., Ltd.
Leukemia, Chronic Myelogenous
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.
- Trial name
- NCT03128411
- Testing
- Bosutinib
- Where
- 21 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Pfizer
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
This is an open label study of the dose and duration of an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, in patients with high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic…
- Trial name
- NCT02842827
- Testing
- bomedemstat, tretinoin
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
AML, Childhood
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pediatric patients (<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
- Trial name
- NCT05077423
- Testing
- CD33*CD3 BsAb
- Where
- 13 sites in United States
- Volunteers
- 3 people
- Sponsor
- Y-mAbs Therapeutics
Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia
WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study
WT1 TCR gene therapy is a new treatment for acute myeloid leukaemia and chronic myeloid leukaemia. Patient's white blood cells (T cells) are modified to specifically fight the leukaemia cells by transferring a gene into the T…
- Trial name
- NCT01621724
- Testing
- WT1 TCR-transduced T cells
- Where
- 2 sites in United Kingdom
- Volunteers
- 7 people
- Sponsor
- Cell Medica Ltd
Chronic Myeloid Leukemia, Chronic Phase
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
This is a Phase III, multi-center, open-label, parallel, 2-arm, randomized study to evaluate the efficacy and safety of radotinib 300 mg Bis In Die(BID) versus imatinib 400 mg Quaque Die(QD).
- Trial name
- NCT03722420
- Testing
- Radotinib, Imatinib
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Acute Myeloid Leukemia
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
To assess the safety and efficacy of galinpepimut-S (GPS) compared with investigator's choice of best available therapy (BAT) on overall survival (OS) in subjects with acute myeloid leukemia (AML) who are in second or later…
- Trial name
- REGAL (NCT04229979)
- Testing
- Galinpepimut-S, Azacitidine, Venetoclax
- Where
- 73 sites in United States, France and 8 more
- Volunteers
- 127 people
- Sponsor
- Sellas Life Sciences Group
Acute Myeloid Leukemia
A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
The purpose of this study is to understand the safety profile of LY2181308 sodium administered in combination with idarubicin and cytarabine to patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT00620321
- Testing
- LY2181308 sodium, cytarabine, idarubicin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
TAA05 Injection in the Treatment of Adult Patients With FLT3-positive Relapsed/Refractory Acute Myeloid Leukemia
This is a single arm , open-label, dose-escalation clinical study with the primary objective of evaluating the safety and tolerability of TAA05 injection in adult subjects with FLT3-positive relapsed/refractory acute myeloid…
- Trial name
- NCT05432401
- Testing
- T cell injection targeting FLT3 chimeric antigen receptor
- Where
- China
- Volunteers
- 18 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
The purpose of this study is to evaluate the safety, tolerability, and preliminary clinical activity of CC-95251 alone and in combination with antineoplastic agents in participants with relapsed or refractory acute myeloid…
- Trial name
- NCT05168202
- Testing
- CC-95251, Azacitidine, Venetoclax
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Myelogenous Leukemia, Chronic
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
It is an open-label, randomized, multi-center study. The efficacy and safety of two flumatinib doses, 400 mg once daily and 600 mg once daily, will be compared with imatinib 400 mg once daily in newly diagnosed (within 6 months)…
- Trial name
- NCT01503502
- Testing
- flumatinib, imatinib
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.